Navigation Links
VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
Date:5/15/2008

n the study are treated once daily with one of three dose levels of VIA-2291 or placebo. "We are very pleased to close enrollment at 191 patients versus our target enrollment of 200 patients as a result of seeing fewer patients fall out of treatment than we initially expected when the trials were designed," said Dr. Rebecca Taub, senior vice president of research and development.

This is the second Phase 2 study of VIA-2291 to complete enrollment. In March 2008, VIA announced completion of enrollment in its Carotid Endarterectomy (CEA) trial, which is designed to provide direct evaluation of VIA-2291's effect on inflammation by analyzing plaque removed from the carotid arteries in patients treated with VIA-2291 or placebo. Enrollment in the third Phase 2 clinical trial, the FDG-PET Trial, is ongoing. Endpoints in this study include reduction in carotid plaque inflammation following dosing with VIA- 2291 as measured with state-of-the-art FDG-PET imaging technology, as well as assessment of standard biomarker measurements of inflammation.

VIA expects to report top line results from the ACS trial soon after top line CEA study results are presented in the third quarter.

About VIA-2291

VIA-2291 is a selective and reversible inhibitor of 5-LO, which is believed to be a key enzyme in the biosynthesis of leukotrienes (important mediators of inflammation involved in the development and progression of atherosclerosis). Potentially a complement to current standard of care therapies that treat risk factors, such as statins, antiplatelet and blood pressure medications, VIA-2291 is initially targeted to address the secondary prevention market for patients who have already suffered a major adverse cardiac event, but eventually could be beneficial to the broader 15.8 million patients in the U.S. who have coronary artery disease. VIA has exclusive worldwide rights to develop and commercialize VIA-2291. Based upon prior trials of VIA-2291 in more than 1,10
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant ... TSX: VRX) announced that the applicable waiting period under ... respect to the previously announced tender offer by its ... of the outstanding shares of common stock of Solta ... a price of $2.92 per share, net to the ...
(Date:1/15/2014)... NEW YORK , Jan. 15, ... a new market research report is ... Global Markets and Technologies ... Focus on Routes of Administration ... STUDY OBJECTIVES A ...
(Date:1/15/2014)... 15, 2014  A novel wearable injector slightly larger ... and painless for patients to self-inject prescription drugs in ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and ... market is expected to grow to $220B by 2018, ... a new type of injector that does not exist ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... Reportlinker.com announces that a new market research report is available ... http://www.reportlinker.com/p0324750/Virtual-Pharma.html ... in the pharmaceutical market has slowed – almost to a ... cutting costs in a faltering world economy. ...
... NEW YORK, Nov. 3, 2010 Pfizer Inc. (NYSE: ... public to view and listen to a webcast of ... Primary Care, at the 2010 Annual Credit Suisse Healthcare ... Mountain Standard Time. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) ...
Cached Medicine Technology:Reportlinker Adds Virtual Pharma 2Reportlinker Adds Virtual Pharma 3Reportlinker Adds Virtual Pharma 4Reportlinker Adds Virtual Pharma 5Reportlinker Adds Virtual Pharma 6
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... boosted 50-fold to 100,000-fold, study finds , , THURSDAY, Dec. 13 ... an international team reports that tiny fibers commonly found in ... its damage. , According to a study in the Dec. ... virus and then ferry it to target cells, increasing its ...
... males and females in order to alleviate back pressure ... research spearheaded at The University of Texas at Austin. ... time in the Dec. 13 issue of Nature. , ... two million years ago, in the early human ancestor ...
... and safety grounds , , THURSDAY, Dec. 13 (HealthDay ... U.S. Food and Drug Administration advisory panel has been asked ... over the counter. , But with groups such as the ... against it, experts think Merck,s proposal is likely to be ...
... to see, the mammalian eye also detects light for a ... the timing of the sleep/wake cycle, which is synchronized by ... hypothalamus. , In a study published online on December ... humans whose non-visual responses to light remain intact, suggesting that ...
... of counseling can reverse seasonal ... stress-related infertility, ... medical specialists are encouraged by new research,pointing toward an age-old ... year-end holiday blues, which doctors say can,actually have physical effects ...
... an advanced,electronic nebulizer, was optimized and used to ... trial. Results of the Phase I trial were,announced ... the Lungs meeting held,in Edinburgh, U.K. ALN-RSV01 is ... respiratory syncytial virus (RSV) infection, the leading,cause of ...
Cached Medicine News:Health News:Fibers in Semen Help HIV Penetrate Cells 2Health News:Adapting to pregnancy played key role in human evolution, study shows 2Health News:FDA Panel Considering Over-the-Counter Statin 2Health News:FDA Panel Considering Over-the-Counter Statin 3Health News:FDA Panel Considering Over-the-Counter Statin 4Health News:FDA Panel Considering Over-the-Counter Statin 5Health News:Blind humans lacking rods and cones retain normal responses to non-visual effects of light 2Health News:Blind humans lacking rods and cones retain normal responses to non-visual effects of light 3Health News:Doctors: Talk Therapy Newest Hope for Treating One Physical Side Effect of Holiday Blues 2Health News:Doctors: Talk Therapy Newest Hope for Treating One Physical Side Effect of Holiday Blues 3Health News:PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study 2
Rhoton #12 straight point needle semisharp, titanium....
Micro 2000, micro scissors micro 2000 supercut....
Micro 2000 suture forceps light-weight instruments with blue-colored anodized round handles, extremely light weight, well balanced, easy to handle, fatigueless working, easy to maintain, corrosion-re...
Mini blades....
Medicine Products: